129 related articles for article (PubMed ID: 11995807)
1. Role of Fas ligand in ocular tissue.
Sano Y; Sotozono C
Cornea; 2002 Mar; 21(2 Suppl 1):S30-2. PubMed ID: 11995807
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas ligand blocks destructive corneal inflammation in mouse models of corneal epithelial debridement and LPS induced keratitis.
Gregory-Ksander M; Perez VL; Marshak-Rothstein A; Ksander BR
Exp Eye Res; 2019 Feb; 179():47-54. PubMed ID: 30365944
[TBL] [Abstract][Full Text] [Related]
3. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
Stuart PM; Griffith TS; Usui N; Pepose J; Yu X; Ferguson TA
J Clin Invest; 1997 Feb; 99(3):396-402. PubMed ID: 9022072
[TBL] [Abstract][Full Text] [Related]
4. Non-cleavable mutant Fas ligand transfection of donor cornea abrogates ocular immune privilege.
Sano Y; Yamada J; Ishino Y; Adachi W; Kawasaki S; Suzuki T; Kinoshita S; Okuyama T; Azuma N
Exp Eye Res; 2002 Oct; 75(4):475-83. PubMed ID: 12387794
[TBL] [Abstract][Full Text] [Related]
5. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
Dupont PJ; Warrens AN
Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
[TBL] [Abstract][Full Text] [Related]
6. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants.
Yamagami S; Kawashima H; Tsuru T; Yamagami H; Kayagaki N; Yagita H; Okumura K; Gregerson DS
Transplantation; 1997 Oct; 64(8):1107-11. PubMed ID: 9355824
[TBL] [Abstract][Full Text] [Related]
7. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.
Gregory MS; Saff RR; Marshak-Rothstein A; Ksander BR
Cancer Res; 2007 Dec; 67(24):11951-8. PubMed ID: 18089826
[TBL] [Abstract][Full Text] [Related]
8. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
[TBL] [Abstract][Full Text] [Related]
9. Soluble Fas ligand expression in the ocular fluids of uveitis patients.
Sotozono C; Sano Y; Suzuki T; Tada R; Ikeda T; Nagata S; Kinoshita S
Curr Eye Res; 2000 Jan; 20(1):54-7. PubMed ID: 10611715
[TBL] [Abstract][Full Text] [Related]
10. The FasLane to ocular pathology-metalloproteinase cleavage of membrane-bound FasL determines FasL function.
Gregory-Ksander M; Marshak-Rothstein A
J Leukoc Biol; 2021 Nov; 110(5):965-977. PubMed ID: 33565149
[TBL] [Abstract][Full Text] [Related]
11. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule.
Hori J; Joyce N; Streilein JW
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):443-52. PubMed ID: 10670474
[TBL] [Abstract][Full Text] [Related]
12. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants.
Kang SM; Braat D; Schneider DB; O'Rourke RW; Lin Z; Ascher NL; Dichek DA; Baekkeskov S; Stock PG
Transplantation; 2000 May; 69(9):1813-7. PubMed ID: 10830216
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid.
Li XK; Okuyama T; Tamura A; Enosawa S; Kaneda Y; Takahara S; Funashima N; Yamada M; Amemiya H; Suzuki S
Transplantation; 1998 Dec; 66(11):1416-23. PubMed ID: 9869081
[TBL] [Abstract][Full Text] [Related]
14. Distinct effects of soluble and membrane-bound fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients.
Audo R; Calmon-Hamaty F; Papon L; Combe B; Morel J; Hahne M
Arthritis Rheumatol; 2014 Dec; 66(12):3289-99. PubMed ID: 25078097
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
[TBL] [Abstract][Full Text] [Related]
16. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis.
Wahlsten JL; Gitchell HL; Chan CC; Wiggert B; Caspi RR
J Immunol; 2000 Nov; 165(10):5480-6. PubMed ID: 11067900
[TBL] [Abstract][Full Text] [Related]
17. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand-induced apoptosis as a mechanism of immune privilege.
Griffith TS; Brunner T; Fletcher SM; Green DR; Ferguson TA
Science; 1995 Nov; 270(5239):1189-92. PubMed ID: 7502042
[TBL] [Abstract][Full Text] [Related]
19. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
O'Connell J
Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
[TBL] [Abstract][Full Text] [Related]
20. Accelerated rejection of Fas ligand-expressing heart grafts.
Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
